BibTex RIS Cite

Yenidoğan Döneminde Anemi ile Semptom Veren Minör Kan Grubu (Anti-C ve Anti-E) Uygunsuzluğuna Bağlı Hemolitik Hastalık

Year 2014, Volume: 8 Issue: 1, 32 - 34, 01.12.2014

Abstract

Erken yenidoğan dönemde hemolitik aneminin en sık nedeni kan grup uyuşmazlıklarıdır. Son dört dekatta anti-D gamaglobulin kullanmının yaygınlaşması ile Rh uyuşmazlıkları azalmış ve minör kan grubu uyuşmazlıklarının yenidoğan hemolitik anemi etiyolojisindeki oranı giderek artmıştır. Bu nedenle major kan grubu uygunsuzluğu bulunmayan ve periferik yaymada hemoliz bulguları olan yenidoğanlarda minör kan grup uyuşmazlığının düşünülmesi önemlidir. Minör kan grubu uyuşmazlığına bağlı olgularda subklinik hemoliz bulgularından aktif hemoliz ve kan değişimi gerektiren yenidoğan sarılığına kadar değişkenlik gösteren tablolar oluşabilir. Bu yazıda erken yenidoğan hatta fetal dönemde ciddi anemi semptomlarını gösteren ve intravenöz immünoglobulin ile hemolizi kontrol altına alınan bir olgu sunulmaktadır.

References

  • Zipursky A, Bowman JM. Isoimmune hemolytic diseases. In: Nathan DG, Oski FA (eds). Hematology of Infancy and Childhood, 4th ed. Philadelphia: WB Saunders C, 1993:44-73.
  • Farnault L, Garcia-Meric P, Cortey A, Arnaud F. Fetomaternal anti- RH3, -4 (anti-E and anti-c) rhesus isoimmunization: A case report. Arch Pediatr 2011;18:176-82.
  • Dajak S, Culic S, Stefanovic V, Lukacevic J. Relationship between previous maternal transfusions and haemolytic disease of the foetus and newborn mediated by non-RhD antibodies. Blood Transfus 2013;5:1-5.
  • To WW, Ho SN, Mok KM. Anti-E alloimmunization in pregnancy: Management dilemmas. J Obstet Gynaecol Res 2003;29: 45-8.
  • Tekşam Ö, Merca YE, Kazancı E, Yiğit Ş. Bir yenidoğanda anti-E antikorlarına bağlı olarak gelişen hemolitik hastalık. Çocuk Sağlığı ve Hastalıkları Dergisi 2005;3: 239-41.
  • Kubo S, Ariga T, Tsuneta H, Ishii T. Can high-dose immunoglobulin therapy be indicated in neonatal rhesus haemolysis? A successful case of haemolytic disease due to rhesus (c + E) incompatibility. Eur J Pediatr 1991;150:507-8.
  • Sato K, Hara T, Kondo T, Iwao H, Honda S, Ueda K. High- dose intravenous gammaglobulin therapy for neonatal immune haemolytic jaundice due to blood group incompatibility. Acta Paediatr Scand 1991;80:163-6.
  • Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV. Intravenous immunoglobulin: An update on the clinical use and mechanisms of action. J Clin Immunol 2007;27:233-45.
  • Hammerman C, Vreman HJ, Kaplan M, Stevenson DK. Intravenous immune globulin in neonatal immune hemolytic disease: Does it reduce hemolysis? Acta Paediatr 1996;85:1351-3.

A Hemolytic Disease due to Minor Blood Group (Anti-C and Anti-E) Incompatibility Leading to Symptomatic Anemia in the Neonatal

Year 2014, Volume: 8 Issue: 1, 32 - 34, 01.12.2014

Abstract

Blood group incompatibility is the most common cause of hemolytic anemia in the early newborn period. The widespread use of anti-D gammaglobulin in the last four decades has decreased the rate of Rh incompatibility and increased the rate of minor blood group incompatibility in the etiology of newborn hemolytic anemia. It is important to consider minor group incompatibility in newborn babies with hemolysis in peripheral blood smears but without major blood group incompatibility. The clinical picture with minor blood group incompatibility may vary from subclinical hemolysis to active hemolysis and newborn jaundice that necessitates transfusion. We present a case with symptoms of severe anemia in the early newborn and even in the fetal period, in whom hemolysis was controlled with intravenous immunoglobulin

References

  • Zipursky A, Bowman JM. Isoimmune hemolytic diseases. In: Nathan DG, Oski FA (eds). Hematology of Infancy and Childhood, 4th ed. Philadelphia: WB Saunders C, 1993:44-73.
  • Farnault L, Garcia-Meric P, Cortey A, Arnaud F. Fetomaternal anti- RH3, -4 (anti-E and anti-c) rhesus isoimmunization: A case report. Arch Pediatr 2011;18:176-82.
  • Dajak S, Culic S, Stefanovic V, Lukacevic J. Relationship between previous maternal transfusions and haemolytic disease of the foetus and newborn mediated by non-RhD antibodies. Blood Transfus 2013;5:1-5.
  • To WW, Ho SN, Mok KM. Anti-E alloimmunization in pregnancy: Management dilemmas. J Obstet Gynaecol Res 2003;29: 45-8.
  • Tekşam Ö, Merca YE, Kazancı E, Yiğit Ş. Bir yenidoğanda anti-E antikorlarına bağlı olarak gelişen hemolitik hastalık. Çocuk Sağlığı ve Hastalıkları Dergisi 2005;3: 239-41.
  • Kubo S, Ariga T, Tsuneta H, Ishii T. Can high-dose immunoglobulin therapy be indicated in neonatal rhesus haemolysis? A successful case of haemolytic disease due to rhesus (c + E) incompatibility. Eur J Pediatr 1991;150:507-8.
  • Sato K, Hara T, Kondo T, Iwao H, Honda S, Ueda K. High- dose intravenous gammaglobulin therapy for neonatal immune haemolytic jaundice due to blood group incompatibility. Acta Paediatr Scand 1991;80:163-6.
  • Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV. Intravenous immunoglobulin: An update on the clinical use and mechanisms of action. J Clin Immunol 2007;27:233-45.
  • Hammerman C, Vreman HJ, Kaplan M, Stevenson DK. Intravenous immune globulin in neonatal immune hemolytic disease: Does it reduce hemolysis? Acta Paediatr 1996;85:1351-3.
There are 9 citations in total.

Details

Other ID JA59FU93ZC
Journal Section Case Report
Authors

İsmail Kürşad Gökçe This is me

Nilüfer Güzoğlu This is me

Mehmet Yekta Öncel This is me

Erhan Çalışıcı This is me

Fuat Emre Canpolat This is me

Uğur Dilmen This is me

Publication Date December 1, 2014
Submission Date December 1, 2014
Published in Issue Year 2014 Volume: 8 Issue: 1

Cite

Vancouver Gökçe İK, Güzoğlu N, Öncel MY, Çalışıcı E, Canpolat FE, Dilmen U. A Hemolytic Disease due to Minor Blood Group (Anti-C and Anti-E) Incompatibility Leading to Symptomatic Anemia in the Neonatal. Türkiye Çocuk Hast Derg. 2014;8(1):32-4.


The publication language of Turkish Journal of Pediatric Disease is English.


Manuscripts submitted to the Turkish Journal of Pediatric Disease will go through a double-blind peer-review process. Each submission will be reviewed by at least two external, independent peer reviewers who are experts in the field, in order to ensure an unbiased evaluation process. The editorial board will invite an external and independent editor to manage the evaluation processes of manuscripts submitted by editors or by the editorial board members of the journal. The Editor in Chief is the final authority in the decision-making process for all submissions. Articles accepted for publication in the Turkish Journal of Pediatrics are put in the order of publication, with at least 10 original articles in each issue, taking into account the acceptance dates. If the articles sent to the reviewers for evaluation are assessed as a senior for publication by the reviewers, the section editor and the editor considering all aspects (originality, high scientific quality and citation potential), it receives publication priority in addition to the articles assigned for the next issue.


The aim of the Turkish Journal of Pediatrics is to publish high-quality original research articles that will contribute to the international literature in the field of general pediatric health and diseases and its sub-branches. It also publishes editorial opinions, letters to the editor, reviews, case reports, book reviews, comments on previously published articles, meeting and conference proceedings, announcements, and biography. In addition to the field of child health and diseases, the journal also includes articles prepared in fields such as surgery, dentistry, public health, nutrition and dietetics, social services, human genetics, basic sciences, psychology, psychiatry, educational sciences, sociology and nursing, provided that they are related to this field. can be published.